Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses

Biochemical Pharmacology

Volumn 66, Issue 8, 2003, Pages 1347-1354

  Chang, Nan Shan ^a   Doherty, Joan ^a   Ensign, Amy ^a   Lewis, Jennifer ^a   Heath, John ^a   Schultz, Lori ^a   Chen, Shur Tzu ^b   Oppermann, Udo ^c  

^a GUTHRIE RESEARCH INSTITUTE   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ADH; Alcohol dehydrogenase; c Jun N terminal kinase; JNK1; NLS; Nuclear localization sequence; SDR; Short chain dehydrogenase reductase; TNF; TRADD; Tumor necrosis factor; WOX1 (or WWOX); WW domain containing oxidoreductase

Indexed keywords

OXIDOREDUCTASE; PROTEIN; PROTEIN WOX1; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; WWOX PROTEIN, HUMAN;

APOPTOSIS; BREAST CANCER; CELL DEATH; CONFERENCE PAPER; GENE; GENETIC CODE; HETEROZYGOSITY; HUMAN; LUNG CANCER; MOLECULAR DYNAMICS; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER; RNA TRANSCRIPTION; STRESS; WWOX GENE; ARTICLE; CELL NUCLEUS; CONGESTIVE HEART FAILURE; METABOLISM; MITOCHONDRION; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TRANSPORT AT THE CELLULAR LEVEL;

APOPTOSIS; BIOLOGICAL TRANSPORT; CELL NUCLEUS; HEART FAILURE, CONGESTIVE; HUMANS; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASES; OXIDOREDUCTASES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; STRESS; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0642283973     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00484-2     Document Type: Conference Paper

References (44)

1. Thiagalingam S., Foy R.L., Cheng K.H., Lee H.J., Thiagalingam A., Ponte J.F. Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Curr. Opin. Oncol. 14(1):2002;65-72. Review.
2. Welcsh P.L., King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum. Mol. Genet. 10(7):2001;705-713. Review.
3. Sluss H.K., Jones S.N. Analysing p53 tumour suppressor functions in mice. Expert Opin. Ther. Targets. 7(1):2003;89-99. Review.
4. Deng C.X. Tumor formation in Brca1 conditional mutant mice. Environ. Mol. Mutagen. 39(2/3):2002;171-177. Review.
5. Bednarek A.K., Laflin K.J., Daniel R.L., Liao Q., Hawkins K.A., Aldaz C.M. WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res. 60(8):2000;2140-2145.
6. Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., Woollatt E., Kremmidiotis G., Gardner A., Venter D., Baker E., Richards R.I. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet. 9(11):2000;1651-1663.
7. Yakicier M.C., Legoix P., Vaury C., Gressin L., Tubacher E., Capron F., Bayer J., Degott C., Balabaud C., Zucman-Rossi J. Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. Oncogene. 20(37):2001;5232-5238.
8. Paige A.J., Taylor K.J., Taylor C., Hillier S.G., Farrington S., Scott D., Porteous D.J., Smyth J.F., Gabra H., Watson J.E. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc. Natl. Acad. Sci. U.S.A. 98(20):2001;11417-11422.
9. Driouch K., Prydz H., Monese R., Johansen H., Lidereau R., Frengen E. Alternative transcripts of the candidate tumor suppressor gene, WWOX, are expressed at high levels in human breast tumors. Oncogene. 21(12):2002;1832- 1840.
10. Kuroki T., Trapasso F., Shiraishi T., Alder H., Mimori K., Mori M., Croce C.M. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 62(8):2002;2258-2260.
11. Li C., Berx G., Larsson C., Auer G., Aspenblad U., Pan Y., Sundelin B., Ekman P., Nordenskjold M., van Roy F., Bergerheim U.S. Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer. Genes Chromosomes Cancer. 24(3):1999;175-182.
12. Suzuki H., Komiya A., Emi M., Kuramochi H., Shiraishi T., Yatani R., Shimazaki J. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer. 17(4):1996;225-233.
13. Yendamuri S., Kuroki T., Trapasso F., Henry A.C., Dumon K.R., Huebner K., Williams N.N., Kaiser L.R., Croce C.M. WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res. 63(4):2003;878-881.
14. Huebner K., Croce C.M. FRA3B and other common fragile sites: the weakest links. Nat. Rev. Cancer. 1(3):2001;214-221.
15. Chang N.-S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., Zevotek N. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J. Biol. Chem. 276(5):2001;3361-3370.
16. Chang N.-S., Doherty J., Ensign A. c-Jun N-terminal kinase 1 (JNK1) physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J. Biol. Chem. 278(11):2003;9195-9202.
17. Chang N.-S. Transforming growth factor-beta1 blocks the enhancement of tumor necrosis factor cytotoxicity by hyaluronidase Hyal-2 in L929 fibroblasts. BMC Cell. Biol. 3(1):2002;8.
18. Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., Bergsagel P.L., Kiguchi K., Brenner A.J., Aldaz C.M. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 61(22):2001;8068-8073.
19. Kallberg Y., Oppermann U., Jornvall H., Persson B. Short-chain dehydrogenases/reductases (SDRs). Eur. J. Biochem. 269(18):2002;4409-4417.
20. Filling C., Berndt K.D., Benach J., Knapp S., Prozorovski T., Nordling E., Ladenstein R., Jornvall H., Oppermann U. Critical residues for structure and catalysis in short-chain dehydrogenases/reductases. J. Biol. Chem. 277(28):2002;25677-25684.
21. Oppermann U.C., Filling C., Jornvall H. Forms and functions of human SDR enzymes. Chem. Biol. Interact. 130-132(1/3):2001;699-705. Review.
22. Baker M.E. Evolution of 17beta-hydroxysteroid dehydrogenases and their role in androgen, estrogen and retinoid action. Mol. Cell. Endocrinol. 171(1/2):2001;211-215. Review.
23. Peltoketo H., Luu-The V., Simard J., Adamski J. 17beta-Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J. Mol. Endocrinol. 23(1):1999;1-11. Review.
24. De La Taille A., Vacherot F., Salomon L., Druel C., Gil Diez De Medina S., Abbou C., Buttyan R., Chopin D. Hormone-refractory prostate cancer: a multi-step and multi-event process. Prostate Cancer Prostatic Dis. 4(4):2001;204-212.
25. Powles T.J. Anti-oestrogenic prevention of breast cancer - the make or break point. Nat. Rev. Cancer. 2(10):2002;787-794. Review.
26. Chang N.-S. A potential role of p53 and WOX1 in mitochondrial apoptosis. Int. J. Mol. Med. 9(1):2002;19-24. Review.
27. Richards R.I. Fragile and unstable chromosomes in cancer: causes and consequences. Trends Genet. 17(6):2001;339-345. Review.
28. Zacchi P., Gostissa M., Uchida T., Salvagno C., Avolio F., Volinia S., Ronai Z., Blandino G., Schneider C., Del Sal G. The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature. 419(6909):2002;853-857.
29. Zheng H., You H., Zhou X.Z., Murray S.A., Uchida T., Wulf G., Gu L., Tang X., Lu K.P., Xiao Z.X. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature. 419(6909):2002;849-853.
30. Chang N.-S. The non-ankyrin C terminus of IκBα physically interacts with p53 in vivo and dissociates in response to apoptotic stress, hypoxia, DNA damage, and transforming growth factor-beta 1-mediated growth suppression. J. Biol. Chem. 277(12):2002;10323-10331.
31. Davis R.J. Signal transduction by the JNK group of MAP kinases. Cell. 103(2):2000;239-252. Review.
32. Chang N.-S. A novel role of IκBα in the JNK and p53-regulated stress and apoptotic responses. Mod. Asp. Immunobiol. 2(5):2002;210-214. Review.
33. MacCorkle-Chosnek R.A., VanHooser A., Goodrich D.W., Brinkley B.R., Tan T.H. Cell cycle regulation of c-Jun N-terminal kinase activity at the centrosomes. Biochem. Biophys. Res. Commun. 289(1):2001;173-180.
34. Roulston A., Reinhard C., Amiri P., Williams L.T. Early activation of c-Jun N-terminal kinase and p38 kinase regulate cell survival in response to tumor necrosis factor alpha. J. Biol. Chem. 273(17):1998;10232-10239.
35. Chang N.-S. IκBα is essential for maintaining basal c-Jun N-terminal kinase (JNK) activation and regulating JNK-mediated resistance to tumor necrosis factor cytotoxicity in L929 cells. Biochem. Biophys. Res. Commun. 263(1):1999;107-112.
36. Chang N.-S. Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death. Biochem. Biophys. Res. Commun. 283(2):2001;278-286.
37. Deng X., Xiao L., Lang W., Gao F., Ruvolo P., May W.S. Jr. Novel role for JNK as a stress-activated Bcl2 kinase. J. Biol. Chem. 276(26):2001;23681- 23688.
38. Mann D.L. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. 91(11):2002;988-998. Review.
39. Bradham W.S., Bozkurt B., Gunasinghe H., Mann D., Spinale F.G. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc. Res. 53(4):2002;822-830. Review.
40. Asher G., Lotem J., Kama R., Sachs L., Shaul Y. NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. U.S.A. 99(5):2002;3099-3104.
41. Yamada T., Goto M., Punj V., Zaborina O., Chen M.L., Kimbara K., Majumdar D., Cunningham E., Das Gupta T.K., Chakrabarty A.M. Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer. Proc. Natl. Acad. Sci. U.S.A. 99(22):2002;14098-14103.
42. Cande C., Cohen I., Daugas E., Ravagnan L., Larochette N., Zamzami N., Kroemer G. Apoptosis-inducing factor (AIF): a novel caspase-independent death effector released from mitochondria. Biochimie. 84(2/3):2002;215-222. Review.
43. Lipton S.A., Bossy-Wetzel E. Dueling activities of AIF in cell death vs. survival: DNA binding and redox activity. Cell. 111(2):2002;147-150. Review.
44. Klein J.A., Longo-Guess C.M., Rossmann M.P., Seburn K.L., Hurd R.E., Frankel W.N., Bronson R.T., Ackerman S.L. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature. 419(6905):2002;367-374.